SVCM
HZNP

Saturn V Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Saturn V Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-111,045
Closed -$12.8M – 26
2023
Q3 		$12.8M Buy
111,045
+11,550
+12% +$1.24M 5.38% 9
2023
Q2 		$10.2M Buy
99,495
+278
+0.3% +$29.3K 5.68% 8
2023
Q1 		$10.8M Buy
99,217
+30,047
+43% +$3.32M 8.09% 4
2022
Q4 		$5.68M Buy
+69,170
New +$5.75M 4.71% 13

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Saturn V Capital Management's HZNP Position: Q4 2023 in Review

Saturn V Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 111,045 shares — an estimated $12.8M sold.

Saturn V Capital Management first reported a position in HZNP in Q4 2022 and held it in 4 quarters. The position peaked at $12.8M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Saturn V Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Saturn V Capital Management sold 111,045 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $12.8M.
  • Saturn V Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 4 quarters.
  • Saturn V Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $12.8M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Saturn V Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.